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a b s t r a c t
Tespa1 has been recently reported to be a critical molecule in T-cell development, however, the precise
molecular mechanisms of Tespa1 remain elusive. Here, we demonstrate that Tespa1 shows amino-acid
sequence homology to KRAS-induced actin-interacting protein (KRAP), an inositol 1,4,5-trisphosphate
receptor (IP3R) binding protein, and that Tespa1 physically associates with IP3R in T and B lymphocytes.
Two-consecutive phenylalanine residues (Phe185/Phe186) in Tespa1, which are conserved between
Tespa1 andKRAP, are indispensable for the association between Tespa1 and IP3R. These ﬁndings suggest
that Tespa1 plays critical roles in the immune system through the regulation of the IP3R.
c© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Intracellular Ca2+ is a versatile, universal second messenger con-
trolling numerous biological processes [1,2]. Three inositol 1,4,5-
trisphosphate receptor (IP3R) subtypes are differentially expressed
among tissues [3–7] and function as the Ca2+ release channel on en-
doplasmic reticulum membranes [8–12]. IP3R is regulated by many
intracellular modulators, phosphorylation by kinases, and associated
proteins [13–17].
KRAS-induced actin-interacting protein (KRAP), originally identi-
ﬁed as one of the deregulated expression genes in colorectal cancer
[18] and also known as sperm-speciﬁc antigen 2 (SSFA2), physiolog-
ically participates in the regulation of systemic energy homeostasis
[19] and of the exocrine system [20]. We have recently demonstrated
that KRAP is involved in the regulation of the proper localization
and function of IP3R through the physical molecular interaction in
the epithelial cells [21–23]. On the other hand, Tespa1 (thymocyte-
expressed positive selection-associated 1) has just recently been re-
ported to play a crucial role in T-cell development in the thymusAbbreviations: Tespa1, thymocyte-expressed positive selection-associated 1; IP3R,
Inositol 1,4,5-trisphosphate receptor; KRAP, KRAS-induced actin-interacting protein.
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http://dx.doi.org/10.1016/j.fob.2012.08.005[24], however, the precise molecular mechanisms of Tespa1 remain
elusive.
We herein report that Tespa1 possesses substantial amino acid
sequence homology to KRAP. Tespa1 is exclusively expressed in T and
B lymphocytes and is functionally related to KRAP; Tespa1 physically
interactswith IP3R in T and B lymphocytes. Thus, our ﬁnding that IP3R
is directly regulated by Tespa1 provides insight into the molecular
mechanism underlying the regulation of IP3R in T and B lymphocytes.
2. Materials and methods
2.1. Antibodies
The antibodies used were as follows: anti-actin (A2066) from
Sigma, anti-hemagglutinin (HA) (3F10) from Roche, anti-green ﬂu-
orescent protein (GFP) (632460) from Clontech, anti-IP3R1 (ab5840)
fromAbcam, anti-IP3R3 (610313) fromBD Transduction Laboratories,
anti-ERK (K-23) from Santa Cruz Biotechnology, and anti-ATP syn-
thase (3D5) from Abcam. The recombinant human Tespa1 fragment
(amino acid residues 2–182) was expressed as a GST fusion protein
using the pGEX4T-2 vector (GE Healthcare). The fusion protein was
soluble in nondenaturing buffer and was puriﬁed with glutathione-
Sepharose 4B (Amersham Pharmacia). Antiserum was obtained by
injecting the recombinant Tespa1 protein into a Japanese White rab-
bit followed by booster injection. Antiserum was puriﬁed with an
afﬁnity column prepared by cross-linking the recombinant protein to.V. Open access under CC BY-NC-ND license.
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CNBr-activated Sepharose 4B (Amersham Pharmacia).
Fig. 1. Tespa1 protein exists in the microsomal fraction in lymphocytes. (A) Western
blot analysis and immunoprecipitations by using anti-Tespa1 antibody for Tespa1 pro-
tein expression in the 12 kinds of adult mouse tissues. ERK is used as a loading control.
WAT, white adipose tissue. (B) Western blot analysis for Tespa1 protein expression
in CD19+, CD4+, CD8+, and CD11b+ cells isolated from the adult mouse spleen. Actin
is used as a loading control. (C) Western blot analysis of Tespa1, IP3R1, IP3R3, ATP
synthase (ATP syn), and actin expressions in the subcellular fractions from the adult
mouse thymus. S3, soluble cytoplasmic fraction; P2, crude mitochondrial fraction; P3,
crude microsomal fraction; total, total lysate; IP, immunoprecipitations.
3
m
w2.2. Animals
All animals used in this study were treated in accordance with the
guidelines of Fukuoka University.
2.3. Cell isolation and subcellular fractionation
Positive selection of a speciﬁc type of lymphocyte was carried out
using MACS microbeads coated with a speciﬁc monoclonal antibody
(Miltenyi Biotec) as described previously [25]. Subcellular fractions
from mouse thymus were obtained as described previously [21].
2.4. Cell culture and transfection
Cell culture and transfection were performed as previously de-
scribed [21].
2.5. Immunoprecipitations and Western blotting
Immunoprecipitations and Western blotting were performed as
previously described [18,21].
2.6. Immunocytochemistry
Immunostaining was performed as described previously [18,21].
2.7. Construction of plasmids
The cDNAs encoding full-length human Tespa1 (residues 2–521)
and its deletion mutants (residues 2–201 and 2–182) were cloned
into the pCMV-HA vector (Clontech). Site-directedmutants of Tespa1
were generated by utilizing the KOD-Plus-Mutagenesis kit (TOYOBO).
The GFP-tagged full-length mouse IP3R1 fusion protein and its dele-
tion mutants were generated as described previously [21]. The cDNA
encoding IP3R1 deletion mutants (residues 611–2749, 2216–2749,
1–230 fused to 2216–2749, and 231–610 fused to 2216–2749) were
cloned into the pEGFP-N1 vector (Clontech).
3. Results and discussion
3.1. Identiﬁcation of Tespa1 as a KRAP-related protein
To explore whether there are structurally and func-
tionally KRAP-related proteins, we used the N-terminal
amino acid sequences of KRAP (residues 1–203 of mouse
KRAP or residues 1–201 of human KRAP) as the query se-
quences for the protein BLAST program (National Center
for Biotechnology Information, http://blast.ncbi.nlm.nih.gov/
Blast.cgi?CMD=Web&PAGE TYPE=BlastHome), and this search
revealed that the gene Tespa1 encodes a KRAP-related protein
(Supplementary data, Fig. S1). NH2-terminal amino acid residues
1–300 of Tespa1, which are conserved between human and mouse
species, showed 50% amino acid sequence similarity with those of
KRAPs (Supplementary data, Fig. S1).
To examine the exact tissue distribution of themouse Tespa1 pro-
tein,Western blot analysis and immunoprecipitation experiments for
the Tespa1 protein in the adult mouse tissues were performed (Fig.
1A). Strong expressions of the Tespa1 protein were detected in the
thymus and spleen, but the protein was rarely detected in the other
tissues when total tissue lysates were used as the samples for West-
ern blotting (Fig. 1A, top). Although weak expressions of the Tespa1
protein were also detected in the immunoprecipitates concentrated
from lung and skeletal muscle by using anti-Tespa1 antibody (Fig. 1A,bottom), Tespa1was found to encode an immune system-speciﬁc pro-
tein. Subsequently, we examined MACS-selected lymphocytes from
the adult mouse spleen to determine the cell-type distribution of the
Tespa1 protein. Among the lymphocytes isolated from the spleen,
Tespa1 was detected in CD19+, CD4+, and CD8+ lymphocytes, but un-
detectable in CD11b+ lymphocytes (Fig. 1B), demonstrating that the
Tespa1 protein is predominantly expressed in B and T lymphocytes
but not in other cell types, such asmonocytes andmacrophages in the
spleen. These results are well-consistent with the previous data that
mRNA expression of Tespa1 is speciﬁcally detected in the lymphoid
tissues, thymus, spleen, and lymph nodes, and is detectable in T and
B lymphocytes, but not in macrophages [24]. In addition, to exam-
ine the subcellular localization of the Tespa1 protein in the mouse
thymus, we carried out a biochemical subcellular fractionation assay
and showed that Tespa1 was exclusively detected in the P3, microso-
mal fraction, which was similar to the expression patterns for IP3R1
and IP3R3 proteins (Fig. 1C). It is of note that KRAP was previously
found to be also fractionated into the microsomal fraction prepared
from the mouse liver [21], which was probably due to the physical
association of KRAP with IP3R on the endoplasmic reticulum mem-
branes [21]. Thus, these observations suggested the possibility that
the Tespa1 protein may also bind to the lumen of the cytosolic side of
the endoplasmic reticulum membranes by interacting with IP3R..2. Tespa1 interacts with IP3R subtypes in T and B lymphocytes
To examine whether Tespa1 interacts with IP3R, anti-Tespa1 im-
unoprecipitation and anti-IP3R3 immunoprecipitation experiments
ere performed using the mouse thymus or spleen, and the results
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Fig. 2. Physical association of Tespa1 with IP3R subtypes. (A) Immunoprecipitations
with anti-Tespa1 (αTespa1) or control (preimmune) antibodies were performed using
the mouse thymus or spleen, followed by Western blotting with anti-Tespa1, anti-
IP3R1, or anti-IP3R3 antibodies. (B) Immunoprecipitations with IP3R3 (αIP3R3) or con-
trol (Ctl.IgG) antibodies were performed using the mouse thymus or spleen, followed
by Western blotting with anti-Tespa1 or anti-IP3R1 antibodies. (C and D) Immunopre-
cipitations with anti-Tespa1 (αTespa1) or control (preimmune) antibodies were per-
formed using B220+–B lymphocytes or CD4+–T lymphocytes isolated from the adult
mouse spleen (C), or using T-cell leukemia lines, Jurkat or EL4 (D), followed byWestern
blotting with anti-Tespa1, anti-IP3R1, or anti-IP3R3 antibodies. IP, Immunoprecipita-
tions; total, total lysate. (E) Confocal immunostaining with anti-Tespa1 and anti-IP3R3
antibodies in Jurkat cells. Blue, 4′ ,6-Diamidino-2-phenylindole (DAPI) staining. Scale
bar, 15 μm. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
showed that Tespa1 interacts with IP3R1 and IP3R3 (Fig. 2A and B). In
addition, co-immunoprecipitation studies using B220+ lymphocytes,
CD4+ lymphocytes, a humanT-cell leukemia line (Jurkat), andamouse
T-cell leukemia line (EL4) conﬁrmed the association between Tespa1
and IP3Rs (Fig. 2C and D). Furthermore, endogenous Tespa1 is well-
colocalized with IP3R3 in Jurkat cells (Fig. 2E). These results showed
that the Tespa1protein bindsmultiple subtypes of IP3R both in tissues
and in cultured cells. It is of note that Tespa1 efﬁciently associated
with both the subtype IP3R1 and the subtype IP3R3 in the thymus
(Fig. 2A), whereas Tespa1 preferentially associated with IP3R3 over
IP3R1 in the spleen (Fig. 2A–D).
3.3. Identiﬁcation of the critical region of IP3R for the association with
Tespa1
To identify the critical region of IP3Rs for the association with
Tespa1, we examined the interactions of several GFP-tagged IP3R1
deletion mutants (Fig. 3A, MI-a–i) with the full-length HA-tagged
Tespa1. The NH2-terminal amino acid residues 1–610, which were
conserved among IP3R subtypes, bound to Tespa1, but the suppressor
Fig. 3. Critical region of IP3R for the association with Tespa1. (A) A schematic illus-
tration of the functional domains of mouse IP3R1 (top) and GFP-tagged IP3R1-deletion
mutants used in this study (bottom). Black ribbon is shown for IP3R1 sequence. Hatched
ribbon is shown for IP3R3 sequence. (B and C) Co-immunoprecipitations using full-
length HA-tagged Tespa1 and deletionmutants of IP3R1. a.a., amino acids; IP, immuno-
precipitations; total, total lysate.
domain (MI-e) or ligand binding domain (MI-f) did not bind to Tespa1
(Fig. 3B and C). These results indicate that amino acid residues 1–610
spanning over these two domains were necessary for the interaction
with Tespa1 (Fig. 3B and C). Because we previously reported that the
interaction of IP3Rs with KRAP is also mediated by the NH2-terminal
amino acid residues 1–610 of IP3Rs [21], the molecular mechanism
underlying the formations of the KRAP–IP3R complex and Tespa1–
IP3R complex would be well-conserved.
3.4. Identiﬁcation of the critical region of Tespa1 for the association
with IP3R
To determine the region of Tespa1 that is critical for the associ-
ation with IP3R, we constructed several HA-tagged human Tespa1
deletion mutants (Fig. 4A, MT-a–c) and examined their interaction
with the full-length of GFP-tagged IP3R1.We found that theMT-b but
not the MT-c interacts with IP3R1, indicating that a span of 19 amino
acid residues (183–201) of human Tespa1 is essential for the inter-
action with IP3R1 (Fig. 4B). Interestingly, this critical region is highly
conserved between human and mouse Tespa1 as well as between
human and mouse KRAP (Fig. 4C). Because we previously found that
two consecutive phenylalanine residues (Phe202/Phe203) in mouse
KRAP are critical for the association of KRAP with IP3R [23], we ex-
changed one or both phenylalanine residue(s) at positions 185 and
186 of human Tespa1 for alanine residues (Fig. 4C), and compared the
IP3R1-binding activity between the resulting proteins and the wild-
type Tespa1 form. Neither the F185A/F186A mutant nor the F185A
mutant boundwith IP3R1, whereas the F186Amutant showed aweak
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Fig. 4. Critical region of Tespa1 for the association with IP3R. (A) A schematic illustra-
tion of human Tespa1 (top) and HA-tagged Tespa1-deletionmutants used in this study
(bottom). (B) Co-immunoprecipitations using full-length IP3R1 anddeletionmutants of
Tespa1. (C) The critical region of Tespa1 required for the IP3R interaction (top). Double
or single amino acid substitutions from phenylalanine to alanine residue(s) within hu-
man Tespa1 (bottom). (D) Co-immunoprecipitations using full-length IP3R and various
mutants of Tespa1 (C). a.a., amino acids; IP, immunoprecipitations; total, total lysate.
interactionwith IP3R1 (Fig. 4D). Together, these results indicated that
a common molecular base, in which two consecutive phenylalanine
residues conserved among the KRAP and Tespa1 proteins are crit-
ical for the association with IP3Rs, underlies the formations of the
KRAP–IP3R complex and Tespa1–IP3R complex.
In this study, we identiﬁed Tespa1 as a structurally and func-
tionally KRAP-related protein; Tespa1 has substantial homology to
KRAP and is a novel binding partner of IP3Rs in T and B lympho-
cytes. Recently, Tespa1 was reported to play critical roles in the pos-
itive selection of thymocytes in vivo [24], based on the analysis of
Tespa1-deﬁcient mice, and also suggested that Tespa1 is involved in
the proper assembly of the Lat signalosome through its interaction
with PLC-γ1 and Grb2 [24,26–31]. This ﬁnding indicates the physi-
ological signiﬁcance of Tespa1 in T-cell antigen receptor signaling in
the immune system. Here, we have clearly demonstrated that Tespa1
is a novel IP3R-interacting protein in T and B lymphocytes, and this
ﬁnding would explain why the severe impairments of calcium ﬂux in
the Tespa1-deﬁcient mice occur [24]. Our ﬁnding is well-consistent
with a recent hypothesis that Tespa1 participates in T-cell signal-
ing through regulating calcium release from endoplasmic reticulum
through interaction with IP3R, after interacting with the Lat signalo-
some [32].
Because Tespa1 is predominantly expressedboth in T lymphocytes
and in B lymphocytes, it is likely that Tespa1would affect calcium sig-
naling through the physical interaction with IP3R in B lymphocytes
as well as T lymphocytes. Interestingly, Tespa1 appeared to prefer-
entially interact with IP3R3 over IP3R1 in splenocytes (Fig. 2A–D),
whereas Tespa1 efﬁciently interacted with both the IP3R subtypes
in the thymus (Fig. 2A), suggesting that Tespa1 may interact with
different subtypes of IP3R according to the cell-type and/or cellular
status. If this is the case, the association between Tespa1 and distinct
IP3R subtypeswould play critical roles in the cell-type-speciﬁc and/or
cellular status-speciﬁc biological processes in the lymphocytes.
In conclusion, we identiﬁed Tespa1 as a novel binding partner of
IP3R in the T and B lymphocytes, and these ﬁndings shed light on
the molecular mechanism underlying calcium signaling through the
regulation of IP3R in the immune system.
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